mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant

Cell, Journal Year: 2022, Volume and Issue: 185(3), P. 457 - 466.e4

Published: Jan. 6, 2022

Language: Английский

---

The emergence and epidemic characteristics of the highly mutated SARS‐CoV‐2 Omicron variant

Journal of Medical Virology, Journal Year: 2022, Volume and Issue: 94(6), P. 2376 - 2383

Published: Feb. 4, 2022

Recently, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant (B.1.1.529) was first identified in Botswana November 2021. It reported to World Health Organization (WHO) on 24. On 26, 2021, according advice of scientists who are part WHO's Technical Advisory Group SARS-CoV-2 Virus Evolution (TAG-VE), WHO defined strain as a concern (VOC) and named it Omicron. Compared other four VOCs (Alpha, Beta, Gamma, Delta), most highly mutated strain, with 50 mutations accumulated throughout genome. The contains at least 32 spike protein, which twice many Delta variant. Studies have shown that carrying can increase infectivity immune escape compared early wild-type VOCs. is becoming dominant countries worldwide brings new challenges preventing controlling disease 2019 (COVID-19). current review article aims analyze summarize information data about biological characteristics amino acid mutations, epidemic characteristics, escape, vaccine reactivity variant, hoping provide scientific reference for monitoring, prevention, development strategies

Language: Английский

---

Plasma Neutralization of the SARS-CoV-2 Omicron Variant

New England Journal of Medicine, Journal Year: 2021, Volume and Issue: 386(6), P. 599 - 601

Published: Dec. 30, 2021

Plasma Neutralization of the SARS-CoV-2 Omicron VariantTo The Editor: newly emerged B.1.1.159(omicron) variant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 1 has a large number changes -32 -in its spike protein relative to that original virus (Wuhan-hu-1), particularly in receptor-binding domain and N-terminal domain, primary targets neutralizing antibodies.Previously, we showed approximately 20 introduced into synthetic polymutant (PMS20) are sufficient for substantial evasion polyclonal antibodies elicited majority persons who have recovered from disease 2019 (Covid-19) or received two doses an mRNA vaccine. Of note, several PMS20 same as similar omicron (Fig. S1 Supplementary Appendix, available with full text this letter at NEJM.org).4][5] In plasma specimens obtained month 6 months after infection had Covid-19, 50% neutralization titer (NT 50 ) values were mean (±SD) 60±47 37±27 times lower than Wuhan-hu-1, respectively, 58±51 32±23 Wuhan-hu-1 S2A andS2B).Similarly, different cohort year NT 34±24 43±23 S2C).

Language: Английский

---

mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant

Nature Medicine, Journal Year: 2022, Volume and Issue: 28(3), P. 477 - 480

Published: Jan. 19, 2022

The Omicron variant of SARS-CoV-2 is causing a rapid increase in infections across the globe. This new concern carries an unusually high number mutations key epitopes neutralizing antibodies on viral spike glycoprotein, suggesting potential immune evasion. Here we assessed serum capacity longitudinal cohorts vaccinated and convalescent individuals, as well monoclonal antibody activity against using pseudovirus neutralization assays. We report near-complete lack polyclonal sera from individuals with two doses BNT162b2 COVID-19 vaccine resistance to different clinical use. However, mRNA booster immunizations resulted significant Omicron. study demonstrates that can critically improve humoral response variant.

Language: Английский

---

Characterization of the novel SARS‐CoV‐2 Omicron (B.1.1.529) variant of concern and its global perspective

Journal of Medical Virology, Journal Year: 2021, Volume and Issue: 94(4), P. 1738 - 1744

Published: Dec. 14, 2021

As the latest identified novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern (VOC), influence Omicron on our globe grows promptly. Compared with last VOC (Delta variant), more mutations were identified, which may address characteristics Omicron. Considering these crucial and their implications including an increase in transmissibility, COVID-19 severity, reduction efficacy currently available diagnostics, vaccines, therapeutics, has been classified as one VOC. Notably, 15 reside receptor-binding domain spike glycoprotein, alter infectivity, neutralizing antibody escape, vaccine breakthrough cases COVID-19. Therefore, present study characterizes mutational hotspots comparison Delta SARS-CoV-2. Furthermore, detailed information was analyzed to characterize global perspective Omicron, transmission dynamic, effect testing, immunity, shall promote progress clinical application basic research. Collectively, data suggest that due continuous variation glycoprotein sequences, use coronavirus-specific attachment inhibitors not be current choice therapy for emerging SARS-CoV-2 VOCs. Hence, we need proceed a sense urgency this matter.

Language: Английский

---

Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic

Environmental Research, Journal Year: 2022, Volume and Issue: 209, P. 112816 - 112816

Published: Jan. 29, 2022

Language: Английский

---

How bad is Omicron? What scientists know so far

Nature, Journal Year: 2021, Volume and Issue: 600(7888), P. 197 - 199

Published: Dec. 2, 2021

Language: Английский

---

Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern

Nature Medicine, Journal Year: 2022, Volume and Issue: 28(3), P. 496 - 503

Published: Jan. 28, 2022

Language: Английский

---

Shifting mutational constraints in the SARS-CoV-2 receptor-binding domain during viral evolution

Science, Journal Year: 2022, Volume and Issue: 377(6604), P. 420 - 424

Published: June 28, 2022

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved variants with substitutions in the spike receptor-binding domain (RBD) that affect its affinity for angiotensin-converting enzyme (ACE2) receptor and recognition by antibodies. These could also shape future evolution modulating effects of mutations at other sites-a phenomenon called epistasis. To investigate this possibility, we performed deep mutational scans to measure on ACE2 binding all single-amino acid Wuhan-Hu-1, Alpha, Beta, Delta, Eta variant RBDs. Some substitutions, most prominently Asn

Language: Английский

---

Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies

Journal of Infection and Public Health, Journal Year: 2022, Volume and Issue: 16(1), P. 4 - 14

Published: Nov. 19, 2022

Newly emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are continuously posing high global public health concerns and panic resulting in waves disease 2019 (COVID-19) pandemic. Depending on the extent genomic variations, mutations adaptation, few gain ability to spread quickly across many countries, acquire higher virulency cause disease, morbidity mortality. These have been implicated lessening efficacy current COVID-19 vaccines immunotherapies break-through viral infections vaccinated individuals recovered patients. Altogether, these could hinder protective herd immunity be achieved through ongoing progressive vaccination. Currently, only variant interest SARS-CoV-2 is Omicron that was first identified South Africa. In this review, we present overview with a special focus variant, its lineages hybrid variants. We discuss hypotheses origin, genetic change underlying molecular mechanism behind transmissibility immune escape variant. Major related including available immunotherapeutics vaccines, transmissibility, severity, mortality discussed. last part, challenges strategies counter amid pandemic presented.

Language: Английский

---